Advertisement
Singapore markets close in 3 hours 39 minutes
  • Straits Times Index

    3,286.87
    -0.88 (-0.03%)
     
  • Nikkei

    38,032.71
    +404.23 (+1.07%)
     
  • Hang Seng

    17,613.93
    +329.39 (+1.91%)
     
  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     
  • Bitcoin USD

    64,239.48
    +88.66 (+0.14%)
     
  • CMC Crypto 200

    1,384.46
    +1.89 (+0.14%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • Dow

    38,085.80
    -375.12 (-0.98%)
     
  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     
  • Gold

    2,347.80
    +5.30 (+0.23%)
     
  • Crude Oil

    83.89
    +0.32 (+0.38%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • FTSE Bursa Malaysia

    1,573.86
    +4.61 (+0.29%)
     
  • Jakarta Composite Index

    7,115.99
    -39.31 (-0.55%)
     
  • PSE Index

    6,573.84
    -1.04 (-0.02%)
     

Analysts Are Bullish on Viking Therapeutics Stock

Analysts Are Bullish on Viking Therapeutics Stock

Viking Therapeutics’ (VKTX) stock price rose ~101% on May 31 following the successful trial results of Madrigal Pharmaceuticals’ (MDGL) NASH drug. Madrigal Pharmaceuticals’ drug has a similar mechanism of action as Viking Pharmaceuticals’ NASH drug. In this part, we’ll discuss Wall Street analysts’ recommendations for Viking Therapeutics stock in the next 12 months.